MCK

As of 2026-10-26, MCK scores 59out of 100 on QNTM’s five-factor quantitative model, a moderate conviction reading. The score blends momentum, quality, volume, value and sentiment, then adjusts for the current macro regime. MCK trades at $992.87, within its fair-value band.

MCK scores 59 out of 100 on QNTM's five-factor model — a moderate reading — neither strongly favored nor flagged for weakness at 59. Its strongest factor is value at 81 (exceptional), where it screens cheap on the model's valuation inputs, followed by momentum at 60. The weakest is quality at 52, where earnings-quality metrics lag. Among Healthcare stocks it ranks in roughly the top 14% of the Healthcare names the model scores.

On valuation, MCK is priced around the middle of its recent range. The blended composite before the macro overlay was 60. Same-sector names the model rates nearby include HALO, VEEV, THC.

This is a descriptive factor read on MCK, recomputed each trading day and shown with its reasoning — not a recommendation to buy, hold or sell. The score reflects where MCK sits on the model's measures today, and can change as new data arrives.

FACTOR BREAKDOWN

VALUATION RANGE

QNTM’s descriptive fair-value band for MCK runs $833.93–$1125.31. Current price $992.87 sits within its fair-value band. This is valuation context, not a price target.

OTHER HEALTHCARE NAMES

QNTM provides quantitative model outputs for informational and educational purposes only. It is not investment advice and QNTM is not a registered investment adviser. Scores are rankings, not buy/sell recommendations. Data as of 2026-10-26.